Expression of S100A16 Is Associated with Biological Aggressiveness and Poor Prognosis in Patients with Bladder Cancer Who Underwent Radical Cystectomy

Hiroki Katsumata; Kazumasa Matsumoto; Kengo Yanagita; Yuriko Shimizu; Shuhei Hirano; Kazuki Kitajima; Dai Koguchi; Masaomi Ikeda; Yuichi Sato; Masatsugu Iwamura

doi:10.3390/ijms241914536

Expression of S100A16 Is Associated with Biological Aggressiveness and Poor Prognosis in Patients with Bladder Cancer Who Underwent Radical Cystectomy

Int J Mol Sci. 2023 Sep 26;24(19):14536. doi: 10.3390/ijms241914536.

Authors

Affiliations

¹ Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan.
² Biofluid Biomarker Center, Niigata University, 8050 ikarashi 2-no-cho, Nishi-ku, Niigata 950-2181, Niigata, Japan.
³ KITASATO-OTSUKA Biomedical Assay Laboratories Co., Ltd., 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0329, Kanagawa, Japan.

Abstract

S100 calcium binding protein A16 (S100A16) is expressed in various cancers; however, there are few reports on S100A16 in bladder cancer (BC). We retrospectively investigated clinical data including clinicopathological features in 121 patients with BC who underwent radical cystectomy (RC). Immunohistochemical staining was performed to evaluate S100A16 expression in archived specimens. Cases with >5% expression and more than moderate staining intensity on cancer cells were considered positive. S100A16 expression was observed in 54 patients (44.6%). Univariate analysis showed that S100A16 expression was significantly associated with age, pT stage, recurrence, and cancer-specific death. Kaplan-Meier analyses showed that patients with S100A16 expression had shorter overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) than those without S100A16 expression. In multivariate analysis, pT stage was an independent prognostic factor for OS and lymph node metastasis for CSS and RFS. S100A16 expression may be a biomarker of a biologically aggressive phenotype and poor prognosis in patients with BC who underwent RC. The PI3k/Akt signaling pathway is probably associated with S100A16 and may be a therapeutic target.

Keywords: AHNAK nucleoprotein 2; S100A16 protein; bladder cancer; cystectomy; immunohistochemistry; urothelial carcinoma.

MeSH terms

Cystectomy*
Humans
Phosphatidylinositol 3-Kinases / metabolism
Retrospective Studies
S100 Proteins / genetics
S100 Proteins / metabolism
Urinary Bladder / pathology
Urinary Bladder Neoplasms* / pathology

Substances

Phosphatidylinositol 3-Kinases
S100A16 protein, human
S100 Proteins

Grants and funding

This study was supported in part by a Parent’s Association (Keyaki Kai) Grant of Kitasato University School of Medicine (to H.K.), by a research grant for young doctors and healthcare professionals Grant of SRL Co., Ltd. (to H.K.), and by JSPS KAKENHI (Grant No. JP21K09355 to K.M.).